natgillin/translations-raw huggingface dataset:
Two main studies, involving 1,162 women, mostly postmenopausal, with HR-positive, HER2-negative breast cancer that had started to spread, showed that Verzenios can prolong the time patients live without their disease getting worse (progression-free survival).
Dve glavni študiji, v kateri je bilo vključenih 1 162 žensk, večinoma po menopavzi, s HR-pozitivnim in HER2-negativnim rakom dojke, ki se je začel širiti, sta pokazali, da lahko zdravilo Verzenios podaljša čas, ki ga bolnice preživijo, ne da bi se jim bolezen poslabšala (preživetje brez napredovanja bolezni).
Verzenios contains the active substance abemaciclib.
Zdravilo Verzenios vsebuje učinkovino abemaciklib.
The active substance in Verzenios, abemaciclib, blocks the activity of enzymes known as cyclindependent kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide.
Učinkovina v zdravilu Verzenios, abemaciklib, zavira dejavnost encimov, ki se imenujejo od ciklina odvisne kinaze (CDK) 4 in 6 in imajo ključno vlogo pri uravnavanju rasti in delitve celic.
In some cancers, including HR-positive breast cancer, the activity of CDK 4 and 6 is increased, which helps the cancer cells to multiply uncontrollably.
Pri nekaterih vrstah raka, vključno s HR-pozitivnim rakom dojke, se dejavnost encimov CDK 4 in 6 poveča, zato se rakave celice lažje nenadzorovano razmnožujejo.
How does Verzenios work?
Kako zdravilo Verzenios deluje?
For the full list of side effects and restrictions of Verzenios, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Verzenios glejte navodilo za uporabo.
In the second study women taking Verzenios and fulvestrant lived on average 16 months without their disease getting worse, compared with 9 months for women taking placebo and fulvestrant.
Ženske, ki so jemale zdravilo Verzenios in fulvestrant, so živele povprečno 16 mesecev, ne da bi se jim bolezen poslabšala, v primerjavi z devetimi meseci pri ženskah, ki so jemale placebo in fulvestrant.
By blocking CDK4 and CDK6, Verzenios slows the growth of HR-positive breast cancer cells.
Zdravilo Verzenios z zaviranjem encimov CDK4 in CDK6 upočasni rast HR-pozitivnih celic raka dojke.
In the first study women taking Verzenios and an aromatase inhibitor (letrozole or anastrozole) lived on average 28 months without their disease getting worse compared with 15 months for women taking placebo (a dummy treatment) and an aromatase inhibitor.
V prvi študiji so ženske, ki so jemale zdravilo Verzenios in zaviralec aromataze (letrozol ali anastrozol), povprečno živele brez poslabšanja bolezni 28 mesecev, v primerjavi s 15 meseci pri ženskah, ki so jemale placebo (zdravilo brez učinkovine) in zaviralec aromataze.
Verzenios used with an aromatase inhibitor or fulvestrant increased the time it took for the disease to get worse in postmenopausal women with HR-positive and HER2-negative breast cancer that is advanced or metastatic.
Zdravilo Verzenios v kombinaciji z zaviralcem aromataze ali fulvestrantom je pri ženskah po menopavzi s HR-pozitivnim in HER2-negativnim rakom dojke, ki je napredoval ali metastaziral, podaljšalo čas do poslabšanja bolezni.
How is Verzenios used?
Kako se zdravilo Verzenios uporablja?
Treatment should continue for as long as the patient is benefitting from it and side effects are tolerable.
Priporočeni odmerek je 150 mg dvakrat na dan. Zdravljenje je treba nadaljevati, dokler ima bolnik od njega korist, neželeni učinki pa so znosni.
Ref.: EMEA/350155/2009 EMEA/H/C/1015
: EMEA/350155/2009 EMEA/H/C/1015
Other information about the vaccine:
Druge informacije o cepivu:
This may help to protect against the disease caused by the virus.
To lahko prispeva k obrambi pred boleznimi, ki jih ta virus povzroča.
This authorisation was based on the authorisation granted to Prepandrix in 2008 (‘informed consent').
To dovoljenje je temeljilo na dovoljenju, ki je bilo leta 2008 odobreno za zdravilo Prepandrix („z obveščenim soglasjem“).
The emulsion contains an ‘adjuvant' (a compound containing oil) to stimulate a better response.
Emulzija vsebuje tudi „adjuvans“ (spojino, ki vsebuje olje) za stimulacijo boljšega odziva.
The Committee recommended that the vaccine be given marketing authorisation.
Odbor je priporočil, da se za cepivo odobri dovoljenje za promet.
A further study looked at the immunogenicity of single or double doses of the vaccine in 437 people aged over 60 years.
Dodatna študija je raziskovala imunogenost enojnih ali dvojnih odmerkov cepiva pri 437 osebah, starejših od 60 let.
These patients needed double doses of the vaccine for protection.
Pri teh bolnikih so bili za zaščito potrebni dvojni odmerki.
What benefit has the vaccine shown during the studies?
Kakšne koristi je cepivo izkazalo med študijami?
It contains parts of influenza (flu) viruses that have been inactivated (killed).
Vsebuje dele virusov (gripe), ki so bili inaktivirani (uničeni).
Adults over 80 years of age may need a double dose of the vaccine (one injection into each shoulder) with a second double dose three weeks later.
Pri odraslih, starejših od 80 let, bo morda potreben dvojni odmerek cepiva (ena injekcija v vsako ramo) z drugim dvojnim odmerkom po treh tednih.
This is a special type of vaccine that is intended to protect against a strain of flu that may cause a future pandemic.
To je posebna vrsta cepiva, namenjena za zaščito proti sevu gripe, ki lahko povzroči pandemijo v prihodnosti.
In elderly people, single doses of this vaccine also met these criteria, except for in the small number of patients aged over 80 years who did not have any protection against the virus at the start of the study.
Pri starejših osebah so enojni odmerki cepiva prav tako zadostili temu merilu razen pri majhnem številu bolnikov, starejših od 80 let, ki na začetku študije niso imeli razvite zaščite proti virusu.
At 21 days after the second injection, 84% of the people receiving the vaccine had levels of antibodies that would protect them against H5N1.
21 dni po drugem injiciranju je imelo 84 % oseb, ki so prejele cepivo, koncentracijo protiteles, ki bi jih zaščitila proti H5N1.
What is the risk associated with the vaccine?
Kakšna tveganja so povezana s cepivom?
According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a prepandemic vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
V skladu z merili, ki jih je določil Odbor za zdravila za uporabo v humani medicini (CHMP), mora prepandemično cepivo, da lahko velja kot primerno, zagotoviti zaščitno koncentracijo protiteles pri vsaj 70 % oseb.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj se brani proti bolezni.
The participants received two injections of the vaccine containing one of four different doses of haemagglutinin.
Sodelujoči so prejeli dve injekciji cepiva, ki sta vsebovali enega od štirih različnih odmerkov hemaglutinina.
The vaccine contains a flu strain called ‘A/VietNam/1194/2004 NIBRG-14' (H5N1).
Cepivo vsebuje sev gripe, imenovan „A/VietNam/1194/2004 NIBRG-14“ (H5N1).
The vaccine is given by injection into the shoulder muscle in two single doses, at least three weeks apart.
Cepivo se daje z injiciranjem v ramensko mišico v dveh enojnih odmerkih v razmiku najmanj treh tednov.
The injections were given 21 days apart.
Injekciji sta bili vbrizgani v razmiku 21 dni.
The main measures of effectiveness were the levels of antibodies against the flu virus in the blood at three different times: before vaccination, on the day of the second injection (day 21) and 21 days later (day
Glavno merilo učinkovitosti je bila koncentracija protiteles proti virusu gripe v krvi v treh različnih obdobjih: pred cepljenjem, na dan prejema druge injekcije (21. dan) ter 21 dni kasneje (42. dan).
Before use, the vaccine is made up by mixing together a suspension that contains the virus particles with an emulsion.
Pred uporabo se cepivo pripravi z mešanjem suspenzije, ki vsebuje delce cepiva, in emulzije.
The main study showed that the vaccine containing 3.75 micrograms of haemagglutinin and the adjuvant produced an antibody response that met these criteria.
Glavna študija je pokazala, da cepivo, ki vsebuje 3,75 mikrograma hemaglutinina in adjuvans, povzroči odziv protiteles, ki zadovolji to merilo.
Health experts are concerned that a future flu pandemic could be caused by the H5N1 strain of the virus.
Zdravstvene strokovnjake skrbi, da bi utegnil naslednjo pandemično gripo povzročiti sev virusa H5N1.
When a person is given the vaccine, the immune system recognises the virus as ‘foreign' and makes antibodies against it.
Ko oseba prejme cepivo, imunski sistem prepozna virus kot „tujek“ in proti njemu razvije protitelesa.
The vaccine has been developed to provide protection against this strain, so that it can be used before or during a flu pandemic.
Cepivo je bilo pripravljeno za zaščito proti temu sevu, tako da ga je mogoče uporabiti pred pandemijo gripe ali med njo.
For the full list of all side effects reported with the vaccine, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi cepiva, glejte navodilo za uporabo.
The main study of the vaccine included 400 healthy adults aged between 18 and 60 years and compared the ability of different doses of the vaccine, with or without the adjuvant, to trigger the production of antibodies (‘immunogenicity').
V glavno študijo cepiva je bilo vključenih 400 zdravih odraslih, starih od 18 do 60 let, v njej pa so primerjali učinkovitost različnih odmerkov virusa, z adjuvansom ali brez njega, pri sprožanju tvorbe protiteles („imunogenost“).
The vaccine should not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at very low levels in the vaccine, such as eggs, chicken protein, ovalbumin (a protein in egg white), formaldehyde, gentamicin sulphate (an antibiotic) and sodium deoxycholate.
Cepivo se ne sme dajati osebam, ki so imele anafilaktično reakcijo (resno alergijsko reakcijo) na katero koli sestavino cepiva ali na katero koli od snovi, ki se v sledeh (v zelo nizkih količinah) nahajajo v cepivu, kot so jajca, piščančje beljakovine, ovalbumin (beljakovina v beljaku), formaldehid, gentamicinijev sulfat (antibiotik) in natrijev deoksiholat.
A flu pandemic happens when a new strain of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world.
Pandemija gripe nastopi, ko se pojavi novi sev virusa gripe, ki se lahko brez težav širi s človeka na človeka, ker ljudje nanj niso imuni (zaščiteni proti njemu).
Why has the vaccine been approved?
Zakaj je bilo cepivo odobreno?
The full EPAR for the vaccine can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za cepivo je na voljo tukaj.
This vaccine contains small amounts of haemagglutinins (proteins from the surface) of the H5N1 virus.
To cepivo vsebuje majhno količino hemaglutininov (beljakovin s površine) virusa H5N1.
What is the vaccine used for?
Za kaj se cepivo uporablja?
The most common side effects with Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals (seen with more than 1 in 10 doses of the vaccine) are headache, arthralgia (joint pain), myalgia (muscle pain), reactions at the site of the injection (hardening, swelling, pain and redness), fever and fatigue (tiredness).
Najpogostejši neželeni učinki prepandemičnega cepiva proti gripi (H5N1) (z delci virionov, inaktiviranega, z adjuvansom) Glaxosmithkline Biologicals (ki so se pojavili pri 1 od 10 odmerkov cepiva) so glavobol, artralgija (bolečine v sklepih), mialgija (bolečine v mišicah), reakcije na mestu injiciranja (zatrdlina, oteklina, bolečina, rdečina), povišana telesna temperatura in utrujenost.
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) (A/VietNam/1194/2004 NIBRG-14)
Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals cepivo proti pandemiji gripe (H5N1) (z delci virionov, inaktivirano, z adjuvansom) (A/Vietnam/1194/2004 (NIBRG-14)
How has the vaccine been studied?
Kako je bilo cepivo raziskano?
Vaccination should be delayed in people who have a sudden fever.
Pri osebah, ki imajo nenadno povišano telesno temperaturo, je treba cepljenje odložiti.
The European Commission granted a marketing authorisation valid throughout the EU for Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals to GlaxoSmithKline Biologicals S.A. on 26 September 2008.
Evropska komisija je dovoljenje za promet z zdravilom, veljavno po vsej EU za zdravilo Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) odobrila družbi GlaxoSmithKline Biologicals S.A. dne 26. septembra 2008.
How does the vaccine work?
Kako cepivo deluje?
How is the vaccine used?
Kako se cepivo uporablja?
What is Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals?
Kaj je prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals?
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals is a vaccine that is given by injection.
Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) Glaxosmithkline Biologicals je cepivo, ki se daje z injiciranjem.
The CHMP decided that the benefits of Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals are greater than its risks for active immunisation against H5N1 subtype of influenza A virus.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi prepandemičnega cepiva proti gripi (H5N1) (z delci virionov, inaktiviranega, z adjuvansom) Glaxosmithkline Biologicals pri aktivni imunizaciji proti podtipu H5N1 virusa gripe A večje od z njim povezanih tveganj.
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals is a ‘prepandemic' vaccine.
Cepivo proti gripi (H5N1) (z delci virusa, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals je „prepandemično“ cepivo.
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals is a vaccine for use in adults to protect against flu caused by the H5N1 strain of the influenza A virus.
Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) Glaxosmithkline Biologicals je cepivo, ki se uporablja za cepljenje odraslih proti gripi, ki jo povzroča sev H5N1 virusa gripe A. Cepivo se daje le v skladu z uradnimi priporočili.
Very rare, not known
Zelo redki, neznani*
• Adults and older people
• Odrasli in starostniki
MARKETING AUTHORISATION NUMBER(S) EU/1/09/532/001 - 007
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/532/001 - 007
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na klopidogrel ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
Their frequency is defined using the following conventions: common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
Some other medicines may influence the use of Clopidogrel Acino or vice versa.
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Klopidogrel Acino in obratno.
Date of latest renewal: 21 march 2014
Datum prve odobritve: 28 julij 2009 Datum zadnjega podaljšanja: 20 marca 2014
You should take Clopidogrel Acino for as long as your doctor continues to prescribe it.
Zdravilo Klopidogrel Acino morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
- a planned surgery (including dental) in the next seven days.
nedaven kirurški poseg (vključno na zobeh) načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets
14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet
Each film-coated tablet contains 3.80 mg of hydrogenated castor oil.
Ena filmsko obložena tableta vsebuje 3,80 mg hidrogeniranega ricinusovega olja.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila : http://www.ema.europa.eu.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel and acetylsalicylic acid for this condition.
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel Acino in acetilsalicilne kisline.
Do not use Clopidogrel Acino if you notice any visible sign of damage of blister or film-coated tablets.
Ne uporabljajte tega zdravila , če opazite vidne znake poškodovanja pretisnega omota ali filmsko obloženih tablet.
If you suffer from severe liver disease.
• če imate hudo jetrno obolenje.
What Clopidogrel Acino is and what it is used for What you need to know before you take Clopidogrel Acino
Kaj je zdravilo Klopidogrel Acino in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Acino
If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
• če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je rana na želodcu ali krvavitev v možganih.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).
Učinkovitost klopidogrela so opazili neodvisno od odmerka ASA (75 - 325 mg enkrat na dan).
Your doctor should have prescribed Clopidogrel Acino plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Zdravnik naj bi vam predpisal zdravilo Clopidogrel Acino skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Izločanje Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Acino.
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden boste vzeli Klopidogrel Acino.
If you experience prolonged bleeding when taking Clopidogrel Acino.
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Acino.
NAME OF THE MARKETING AUTHORISATION HOLDER Acino AG
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Acino AG
If you take more Clopidogrel Acino than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Če ste vzeli večji odmerek zdravila Klopidogrel Acino, kot bi smeli Zaradi povečanega tveganja krvavitve se posvetujte s svojim zdravnikom ali oddelkom najbližje bolnišnične nujne zdravniške pomoči.
What you need to know before you take Clopidogrel Acino
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Acino
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
V študiji CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom.
Do not take Clopidogrel Acino:
Ne jemljite zdravila Klopidogrel Acino:
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Acino in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Klopidogrel Acino v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
If you forget to take a dose of Clopidogrel Acino, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time.
Če ste pozabili vzeti zdravilo Klopidogrel Acino Če pozabite vzeti odmerek zdravila Klopidogrel Acino in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
Then, the recommended dose is one 75 mg tablet of Clopidogrel Acino per day as described above.
Nato je priporočeni odmerek ena 75-mg tableta zdravila Klopidogrel Acino na dan, kot je opisano zgoraj.
• if you have had an allergy or reaction to any medicine used to treat your disease.
• če imate ledvične ali jetrne bolezni • če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali
- a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues,
krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih,
Clopidogrel Acino with food and drink Clopidogrel Acino may be taken with or without food.
Zdravilo Klopidogrel Acino skupaj s hrano in pijačo Zdravilo Klopidogrel Acino lahko jemljete s hrano ali brez nje.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) tekom 0 - 1, 1 - 3, 3 - 6, 6 - 9 oziroma 9 - 12 mesečnimi intervali študije.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Acino.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Acino.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina, ki je prisotna v številnih zdravilih proti bolečinam in za zniževanje zvišane telesne temperature, kakor tudi za preprečevanje strjevanja krvi).